Reviewing Voyager Therapeutics Inc. (VYGR)’s and Precision BioSciences Inc. (NASDAQ:DTIL)’s results

Voyager Therapeutics Inc. (NASDAQ:VYGR) and Precision BioSciences Inc. (NASDAQ:DTIL) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Voyager Therapeutics Inc. 14 0.00 24.86M -1.63 0.00
Precision BioSciences Inc. 14 0.00 36.69M -1.74 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Voyager Therapeutics Inc. and Precision BioSciences Inc.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Voyager Therapeutics Inc. 179,494,584.84% -57.3% -15.8%
Precision BioSciences Inc. 262,822,349.57% -91.9% -41.7%

Liquidity

Voyager Therapeutics Inc.’s Current Ratio is 4.1 while its Quick Ratio is 4.1. On the competitive side is, Precision BioSciences Inc. which has a 9.3 Current Ratio and a 9.3 Quick Ratio. Precision BioSciences Inc. is better positioned to pay off short and long-term obligations compared to Voyager Therapeutics Inc.

Analyst Ratings

Voyager Therapeutics Inc. and Precision BioSciences Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Voyager Therapeutics Inc. 0 1 0 2.00
Precision BioSciences Inc. 0 0 0 0.00

The consensus target price of Voyager Therapeutics Inc. is $26, with potential upside of 81.69%.

Institutional & Insider Ownership

Institutional investors owned 83.4% of Voyager Therapeutics Inc. shares and 44.4% of Precision BioSciences Inc. shares. Insiders owned 6.29% of Voyager Therapeutics Inc. shares. Comparatively, 11.6% are Precision BioSciences Inc.’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Voyager Therapeutics Inc. 2.49% 1.53% -15.48% -40.54% 31.14% 48.72%
Precision BioSciences Inc. 10.64% 142.42% 144.22% 52.05% 0% 12.73%

For the past year Voyager Therapeutics Inc.’s stock price has bigger growth than Precision BioSciences Inc.

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The companyÂ’s lead clinical candidate is the VY-AADC01, which is in Phase Ib clinical trial for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for HuntingtonÂ’s disease; VY-FXN01 for Friedreich's ataxia; VY-TAU01, AlzheimerÂ’s disease; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with Genzyme Corporation and the University of Massachusetts. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.